AIA
BMY.RT

AIMZ Investment Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

AIMZ Investment Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22,705
Closed -$81K – 102
2020
Q2 		$81K Hold
22,705
– – 0.05% 96
2020
Q1 		$86K Hold
22,705
– – 0.07% 87
2019
Q4 		$68K Buy
+22,705
New +$59K 0.04% 99

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AIMZ Investment Advisors's BMY.RT Position: Q3 2020 in Review

AIMZ Investment Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 22,705 shares — an estimated $81K sold.

AIMZ Investment Advisors first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $86K in Q1 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • AIMZ Investment Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • AIMZ Investment Advisors sold 22,705 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $81K.
  • AIMZ Investment Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • AIMZ Investment Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $86K in Q1 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on AIMZ Investment Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.